← Back to Search

Radiation Therapy

Advanced Imaging for Prostate Cancer

N/A
Waitlist Available
Led By Peter Chung, MD
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Low or intermediate risk localized prostate cancer: Gleason score ≤ 7, PSA <20, Stage T2a or less, <50% of biopsy cores involved with tumor
Be older than 18 years old
Must not have
Severe adverse event with prior TRUS-guided prostate biopsy
Patient refuses fiducial marker placement
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will study whether reducing the amount of radiation delivered to normal tissues during prostate cancer treatment improves patient outcomes.

Who is the study for?
This trial is for men with low or intermediate risk localized prostate cancer, specifically those with a Gleason score of 7 or less, PSA under 20, and no more than half of biopsy cores involved with tumor. It's not for men who've had hip replacements, inflammatory bowel diseases, severe reactions to prostate biopsies, or are on certain anticoagulant therapies.
What is being tested?
The study tests if using advanced MRI in planning and daily CBCT imaging during treatment can improve outcomes by reducing radiation doses to non-cancerous parts like the rectum and bladder. The trial has two stages: first integrating advanced imaging without changing dose plans; secondly reducing doses to healthy tissues.
What are the potential side effects?
While the trial focuses on minimizing side effects by precisely targeting radiation, potential risks may include typical radiotherapy side effects such as skin irritation at the treatment site, fatigue, urinary issues, and gastrointestinal discomfort.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My prostate cancer is at an early stage, with a low Gleason score, PSA under 20, and limited tumor involvement.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I had a severe reaction to a previous prostate biopsy.
Select...
I refuse to have fiducial marker placement.
Select...
I am not receiving a specific prostate cancer radiation treatment of 78Gy in 39 doses.
Select...
I have inflammatory bowel disease or a connective tissue disorder.
Select...
I cannot safely stop my blood thinner medication.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: MRI + CBCT in prostate cancerExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor
1,523 Previous Clinical Trials
503,243 Total Patients Enrolled
66 Trials studying Prostate Cancer
15,592 Patients Enrolled for Prostate Cancer
Princess Margaret Hospital, CanadaOTHER
119 Previous Clinical Trials
38,969 Total Patients Enrolled
9 Trials studying Prostate Cancer
9,540 Patients Enrolled for Prostate Cancer
Peter Chung, MDPrincipal InvestigatorUniversity Health Network, Toronto
3 Previous Clinical Trials
227 Total Patients Enrolled
2 Trials studying Prostate Cancer
17 Patients Enrolled for Prostate Cancer
~5 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top